GLPwatch
Papers (9189)
Page 118 of 154, ranked by citation count.
- Consumer group calls for antidiabetes drug to be withdrawn.
- Liraglutide improves antioxidant defense in hearts of spontaneously hypertensive female rats independently of changes in blood pressure in a pre-clinical model of menopause.
- Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes.
- Type 2 diabetes: which drug as add-on to metformin?
- In type 2 diabetes with increased CV risk, tirzepatide reduced HbA<sub>1c</sub> vs. glargine at 52 wk.
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
- Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
- Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.
- Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.
- Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review.
- Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.
- Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.
- Liraglutide in islet transplantation: from bench to bedside.
- At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
- A Case of Dulaglutide-Induced Vaginal Bleed.
- Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice.
- Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort.
- Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.
- Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.
- Oral GLP-1 Receptor Agonists for Weight Loss.
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.
- A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.
- Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment.
- Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
- Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas.
- No More Needles: Oral Semaglutide for Weight Loss.
- One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.
- Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
- Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells.
- Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework.
- In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.
- GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm.
- The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics.
- A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.
- Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.
- Research digest.
- Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review.
- Design of experiments approach for the development of a validated method to determine the exenatide content in poly(lactide-co-glycolide) microspheres.
- The effect of human serum albumin glycation on the binding of antidiabetic agent-exenatide; the multispectroscopic studies. Part II.
- Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
- Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
- Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides.
- The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
- Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice.
- [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
- Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
- Exenatide once weekly: opportunities in the primary care setting.
- Liraglutide is an effective drug for the treatment of obesity also in real life.
- Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
- Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.
- Blinded by the drug? A vigilyze signal linking semaglutide to NAION.
- Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.
- Tinkering with weight loss medication in clinical encounters: An ethnographic study.
- Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease.
- A new era in obesity treatment.
- The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
- Obesity Treatment: A Focus on Pharmacotherapy of Weight Management.
- Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data.